Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Cimicoxib, a Selective COX-2 Inhibitor, in Combination With Sertraline Compared to Sertraline Combined With Placebo in Treatment of Major Depression

NCT00510822 is registered in ClinicalTrials.gov with Affectis Pharmaceuticals AG as lead sponsor.

NCT NCT00510822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00510822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Cimicoxib, a Selective COX-2 Inhibitor, in Combination With Sertraline Compared to Sertraline Combined With Placebo in Treatment of Major Depression
Lead sponsor
Affectis Pharmaceuticals AG
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
February 28, 2010
Enrollment
169 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

major depression